non-invasive-testing
(5)
Semler Scientific
One company, two ledgers: a five-minute artery test that scans for hidden vascular disease, and a corporate treasury that traded idle cash for Bitcoin.
SpotitEarly
SpotitEarly is a healthtech company building an accessible, non-invasive early cancer detection service that combines trained scent-detection beagles with an AI platform to analyze volatile organic compounds (VOCs) in a person's breath. Users collect a breath sample at home and mail it to the company's lab, where beagles screen for cancer-linked odors and SpotitEarly's proprietary LUCID bio-AI platform digitizes and interprets the dogs' behavioral signals. A double-blind clinical study of 1,400 people, published in Nature's Scientific Reports, reported 94% sensitivity and specificity across the four most common cancers - breast, colorectal, lung, and prostate. Founded in Israel and now launching in the U.S., the company aims to make routine multi-cancer pre-screening affordable, at roughly $250 for a single test.
Azumio Inc.
Azumio is a Redwood City, California digital health company that builds AI-powered mobile apps and developer APIs for tracking heart rate, food, sleep, fitness and diabetes. Founded in 2011 out of the runaway success of its Instant Heart Rate app, Azumio's consumer titles - including Argus, Calorie Mama, Glucose Buddy, Fitness Buddy and Sleep Time - have collectively surpassed 100 million downloads. The company also licenses its computer-vision technology to businesses through the Calorie Mama / Food Lens food-recognition API and its Instant Diabetes Test and health-data platform APIs.
CorVista Health
CorVista Health is a medical technology company applying machine learning to cardiovascular diagnostics. Its FDA-cleared CorVista System is a non-invasive, point-of-care device that captures cardiac and hemodynamic signals and analyzes them in the cloud to assess the likelihood of coronary artery disease and pulmonary hypertension - delivering results in minutes, without radiation, contrast, injections, fasting, or exercise. The company aims to shorten the path from symptoms to diagnosis so patients can be treated earlier.
ClearNote Health
ClearNote Health is a San Diego molecular diagnostics company building non-invasive, blood-based tests that detect high-mortality cancers early, when treatment works best. Spun out of Stephen Quake's Stanford lab in 2016 (originally as Bluestar Genomics), it pairs a proprietary 5-hydroxymethylcytosine (5hmC) epigenomic platform with cell-free DNA analysis and machine learning. Its flagship Avantect Pancreatic Cancer Test targets high-risk patients - including adults 50+ newly diagnosed with type 2 diabetes - and the company is extending the approach to ovarian and multi-cancer detection.